(BUSINESS WIRE)--CatalYm today announced that the first results from its ongoing Phase 2a trial “GDFATHER-2” (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 2) will be featured in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 in...